国际病毒学杂志
國際病毒學雜誌
국제병독학잡지
INTERNATIONAL JOURNAL OF VIROLOGY
2015年
3期
161-164
,共4页
逍遥散%肝郁气滞%慢性乙型肝炎%近远期疗效%肝功能
逍遙散%肝鬱氣滯%慢性乙型肝炎%近遠期療效%肝功能
소요산%간욱기체%만성을형간염%근원기료효%간공능
Xiaoyaosan%Liver depression symptoms%Chronic hepatitis B%Near and long term efficacy%Liver function
目的 探究逍遥散治疗肝郁气滞症候乙型肝炎的近远期临床疗效,为临床研究提供参考依据.方法 选择2011年4月-2014年3月期间我院收治的82例乙型肝炎患者,按照随机数字法分为实验组和对照组,分别为40例与42例.对照组患者给予西利宾胺治疗实验组患者则服用逍遥散治疗.比较两组患者治疗前后肝功能指标的变化,分析两组患者治疗以后近远期临床疗效的差别.结果 治疗前,两组患者的ALT、AST以及TBIL的水平无差异性(P＞0.05).治疗后,两组患者的ALT、AST以及TBIL的水平较治疗前均显著性降低,具有显著性差异(P＜0.05),但实验组患者的三项生化指标的水平较对照组患者治疗后的水平降低更为明显,具有统计学意义(P＜0.05);治疗后,实验组患者显效21例,有效16例,无效3例,总有效率92.5％,显著高于对照组患者的57.1％的总有效率,具有明显差异性(P＜0.05);治疗前,两组患者的症候积分无显著差异(P＞0.05).治疗0.5年、2年、3年后,两组患者的症候积分均降低,但实验组患者的症候积分与治疗前以及对照组患者治疗后,降低更为明显,均具有显著性差异(P＜0.05).结论 使用逍遥散治疗肝郁气滞证侯乙型肝炎患者,能够显著降低ALT、AST以及TBIL的水平,提高乙型肝炎患者近期临床疗效,改善患者的远期中医证候积分,值得在临床上广泛推广.
目的 探究逍遙散治療肝鬱氣滯癥候乙型肝炎的近遠期臨床療效,為臨床研究提供參攷依據.方法 選擇2011年4月-2014年3月期間我院收治的82例乙型肝炎患者,按照隨機數字法分為實驗組和對照組,分彆為40例與42例.對照組患者給予西利賓胺治療實驗組患者則服用逍遙散治療.比較兩組患者治療前後肝功能指標的變化,分析兩組患者治療以後近遠期臨床療效的差彆.結果 治療前,兩組患者的ALT、AST以及TBIL的水平無差異性(P＞0.05).治療後,兩組患者的ALT、AST以及TBIL的水平較治療前均顯著性降低,具有顯著性差異(P＜0.05),但實驗組患者的三項生化指標的水平較對照組患者治療後的水平降低更為明顯,具有統計學意義(P＜0.05);治療後,實驗組患者顯效21例,有效16例,無效3例,總有效率92.5％,顯著高于對照組患者的57.1％的總有效率,具有明顯差異性(P＜0.05);治療前,兩組患者的癥候積分無顯著差異(P＞0.05).治療0.5年、2年、3年後,兩組患者的癥候積分均降低,但實驗組患者的癥候積分與治療前以及對照組患者治療後,降低更為明顯,均具有顯著性差異(P＜0.05).結論 使用逍遙散治療肝鬱氣滯證侯乙型肝炎患者,能夠顯著降低ALT、AST以及TBIL的水平,提高乙型肝炎患者近期臨床療效,改善患者的遠期中醫證候積分,值得在臨床上廣汎推廣.
목적 탐구소요산치료간욱기체증후을형간염적근원기림상료효,위림상연구제공삼고의거.방법 선택2011년4월-2014년3월기간아원수치적82례을형간염환자,안조수궤수자법분위실험조화대조조,분별위40례여42례.대조조환자급여서리빈알치료실험조환자칙복용소요산치료.비교량조환자치료전후간공능지표적변화,분석량조환자치료이후근원기림상료효적차별.결과 치료전,량조환자적ALT、AST이급TBIL적수평무차이성(P＞0.05).치료후,량조환자적ALT、AST이급TBIL적수평교치료전균현저성강저,구유현저성차이(P＜0.05),단실험조환자적삼항생화지표적수평교대조조환자치료후적수평강저경위명현,구유통계학의의(P＜0.05);치료후,실험조환자현효21례,유효16례,무효3례,총유효솔92.5％,현저고우대조조환자적57.1％적총유효솔,구유명현차이성(P＜0.05);치료전,량조환자적증후적분무현저차이(P＞0.05).치료0.5년、2년、3년후,량조환자적증후적분균강저,단실험조환자적증후적분여치료전이급대조조환자치료후,강저경위명현,균구유현저성차이(P＜0.05).결론 사용소요산치료간욱기체증후을형간염환자,능구현저강저ALT、AST이급TBIL적수평,제고을형간염환자근기림상료효,개선환자적원기중의증후적분,치득재림상상엄범추엄.
Objective To observe the near and long term clinical effect of Xiaoyaosan in treatment of chronic hepatitis B with liver depression symptoms and to provide reference for clinical research.Methods From Apr 2011 to Mar 2014,82 cases of patients with chronic hepatitis B were randomly divide into experimental group (40 cases) and control group (42 cases).The experimental group was treated with Xiaoyaosan and the control group was treated with West libin amine.The liver function index,the near and long term effect were compared between two groups.Results The ALT,AST and TBIL had no significant difference before treatment (P ＞ 0.05) and they had a significant difference after treatment (P ＜ 0.05) between two groups.The liver function index was more improved in experimental group (P ＜ 0.05).The total effective rate of experimental group (92.5％) was significantly higher than that of the control group (57.1％) after treatment (P ＜0.05).The symptoms integral had no significant difference before treatment between two groups (P ＞0.05).0.5 year,2 years and 3 years after treatment,the symptoms integral in two groups were all reduced and experimental group had a significant decrease than that in control group (P ＜0.05).Conclusions Chinical effect was abvious for Xiaoyaosan to treat chronic hepatitis B for significantly reducing the ALT,AST and TBIL levels,enhancing the near clinical effect of patients with hepatitis B and improve the forward TCM syndrome integral,which was worth to expand upon its clinical application.
